ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Frequency and Prognostic Impact of
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06502210 (Identification of New Gene Spliceosomes in Neuroblastoma and Their Translational Application in Clinical Accurate Diagnosis and Therapy), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of New Gene Spliceosomes in Neuroblastoma and Their Translational Application in Clinical Accurate Diagnosis and Therapy
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.Targeted oncology · 2024Pooled it
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.JCO precision oncology · 2026Article
- Lorlatinib monotherapy or combination therapy in anaplastic lymphoma kinase-driven high-risk neuroblastoma.NPJ precision oncology · 2026Article
- International neuroblastoma risk group consortium: a model of networking for rare cancers.Journal of the National Cancer Institute · 2026Article
- Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.The Journal of clinical investigation · 2026Article
- Established and Emerging Therapies for High-Risk Neuroblastoma.Paediatric drugs · 2026Review
- Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.Cancers · 2026Article
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.Frontiers in immunology · 2026Review
- Developmentally relevant proteins contribute to chemotherapeutic resistance in neuroblastoma.Frontiers in oncology · 2026Review
- Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma.Cell reports. Medicine · 2025Article
- Integration of ALK gene mutations and targeted therapies in pediatric high-risk neuroblastoma: advancements in precision oncology.Annals of medicine and surgery (2012) · 2025Review
- High-dose DFMO alters protein translation in neuroblastoma.Neoplasia (New York, N.Y.) · 2025Article
- Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.Molecular cancer therapeutics · 2025Article
- A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.Nature communications · 2025Article
- Selective targeting of genome amplifications and repeat elements by CRISPR-Cas9 nickases to promote cancer cell death.Nature communications · 2025Article
- SNP array analysis facilitates the identification of novel chromosomal alterations associated with disease and SNPs related to adverse drug reactions in neuroblastoma.Oncology letters · 2025Article
- 15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.Current oncology reports · 2025Review
- Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.European journal of cancer (Oxford, England : 1990) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 20 institutions in 15 countries.
Angela BelliniEquipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France.
Ulrike PötschgerDepartment for Studies and Statistics and Integrated Research, Vienna, Austria.ORCID 0000-0001-7024-7082
Virginie BernardInstitut Curie Genomics of Excellence (ICGex) Platform, Research Center, Institut Curie, Paris, France.
Eve LapoubleUnité de Génétique Somatique, Service de Génétique, Hospital Group, Institut Curie, Paris, France.ORCID 0000-0003-3374-3671
Sylvain BaulandeInstitut Curie Genomics of Excellence (ICGex) Platform, Research Center, Institut Curie, Paris, France.ORCID 0000-0003-3104-1684
Peter F AmbrosSt Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0002-5507-7211
Nathalie AugerService de Génétique des tumeurs; Institut Gustave Roussy, Villejuif, France.
Klaus BeiskeDepartment of Pathology, Oslo University Hospital, and Medical Faculty, University of Oslo, Oslo, Norway.ORCID 0000-0002-7772-7748
Marie BernkopfSt Anna Children's Cancer Research Institute, Vienna, Austria.
David R BettsDepartment of Clinical Genetics, Children's Health Ireland at Crumlin, Dublin, Ireland.
Jaydutt BhalshankarEquipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France.
Nick BownNorthern Genetics Service, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Katleen de PreterGhent University, Ghent, Belgium.
Nathalie ClémentEquipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France.
Valérie CombaretTranslational Research Laboratory, Centre Léon Bérard, Lyon, France.
Jaime Font de MoraInstituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID 0000-0002-6816-2095
Sally L GeorgeDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-2777-4922
Irene JiménezEquipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France.
Marta JeisonSchneider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel.
Barbara MarquesDepartamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
Tommy MartinssonSahlgrenska University Hospital, Göteborg, Sweden.ORCID 0000-0002-9403-3123
Katia MazzoccoDepartment of Pathology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0002-6599-5681
Martina MoriniLaboratory of Molecular Biology, IRCCS Istituto Giannina Gaslini, Genova, Italy.ORCID 0000-0003-2569-4515
Annick Mühlethaler-MottetPediatric Hematology-Oncology Research Laboratory, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-8274-0907
Rosa NogueraDepartment of Pathology, Medical School, University of Valencia-Incliva Health Research Institute/CIBERONC, Madrid, Spain.ORCID 0000-0003-4546-7459
Gaelle PierronUnité de Génétique Somatique, Service de Génétique, Hospital Group, Institut Curie, Paris, France.ORCID 0000-0002-2536-7680
Maria RossingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Sabine Taschner-MandlSt Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0002-1439-5301
Nadine Van RoyGhent University, Ghent, Belgium.
Ales VichaDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Louis CheslerPaediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, Sutton, United Kingdom.ORCID 0000-0001-7842-2068
Walentyna BalwierzDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.ORCID 0000-0002-5379-2318
Victoria CastelClinical and Translational Oncology Research Group, Health Research Institute La Fe, Valencia, Spain.ORCID 0000-0002-3792-0615
Martin ElliottLeeds Children's Hospital, Leeds General Infirmary, Leeds, United Kingdom.
Per KognerKarolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-2202-9694
Geneviève LaureysDepartment of Paediatric Haematology and Oncology, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent, Belgium.
Roberto LukschPaediatric Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Josef MalisDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Maja Popovic-BeckPediatric Hematology-Oncology Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9502-5697
Shifra AshRuth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
Olivier DelattreINSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France.ORCID 0000-0002-8730-2276
Dominique Valteau-CouanetDépartement d'Oncologie Pédiatrique, Gustave Roussy, Villejuif, France.
Deborah A TweddleWolfson Childhood Cancer Research Centre, Newcastle Centre for Cancer, Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.ORCID 0000-0003-2208-3970
Ruth LadensteinDepartment for Studies and Statistics and Integrated Research, St Anna Children's Hospital, St Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0001-6548-3873
Gudrun SchleiermacherEquipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France.ORCID 0000-0002-0133-5879
Inserm · FRInstitut Curie · FRSt Anna Children's Hospital · ATGhent University Hospital · BECharles University · CZInstitute of Cancer Research · GBInstitut Gustave Roussy · FRIstituto Giannina Gaslini · ITUniversity of Lausanne · CHCentre Léon Bérard · FRChildren's Health Ireland at Crumlin · IECopenhagen University Hospital · DKFondazione IRCCS Istituto Nazionale dei Tumori · ITInstituto de Investigación Sanitaria La Fe · ESJagiellonian University · PLKarolinska University Hospital · SELeeds General Infirmary · GBNational Institute of Health Dr. Ricardo Jorge · PTNewcastle University · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GB
Funding
Cancer Research UK 8177Department of Health
Abstract
purposeIn neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied MATERIALS AND
methodsDiagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine
resultsGenomic
conclusionGenetic alterations of
Indexed as
Gene AmplificationMutation RateAnaplastic Lymphoma KinaseChild, PreschoolClinical Trials, Phase III as TopicEuropeFemaleFollow-Up StudiesHumansInfantMaleNeuroblastomaN-Myc Proto-Oncogene ProteinPrognosisRandomized Controlled Trials as TopicRisk FactorsAnaplastic Lymphoma KinaseMYCN protein, humanN-Myc Proto-Oncogene Protein
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06502210ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.